New U.S. investment bank joins, bringing total coverage to ten analysts
Read moreIt has been today announced that they has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071...
Read moreTo discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial in BPD
Read morePORTICO-2 designed to validate vafidemstat’s efficacy in reducing aggression in BPD patients
Read moreAgitation/Aggression in PMS and other ASD-related patient subpopulations are the main focus of Oryzon’s VANDAM project included in the Med4Cure IPCEI project
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will give an update on corporate progress at several intern...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today reported financial results for the first quarter ended Marc...
Read moreOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases
Read moreIt has been announced today the successful completion of a €30 million capital increase through the issuance of 12,765,958 new shares, priced at €2.35 per share. This pricing reflects a 15.44%
Read moreThe patent, titled “Methods of treating Attention Deficit Hyperactivity Disorder using KDM1A inhibitors such as the compound vafidemstat”, covers the use Oryzon’s LSD1 inhibitor, vafidemstat, cu...
Read moreOryzon Genomics announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibi...
Read moreLa compañía se suma nuevamente a la iniciativa impulsada por la Fundación "la Caixa" en colaboración con Gavi, the Vaccine Alliance. Esta acción solidaria respalda el ODS3 de las Naciones Unidas,...
Read more